-
Something wrong with this record ?
Does status epilepticus modify the effect of ifenprodil on cortical epileptic afterdischarges in immature rats
K. Abbasova, H. Kubová, P. Mareš,
Language English Country Poland
Document type Comparative Study, Journal Article
- MeSH
- Excitatory Amino Acid Antagonists pharmacology MeSH
- Anticonvulsants pharmacology MeSH
- Lithium Chloride MeSH
- Electric Stimulation MeSH
- Disease Models, Animal MeSH
- Cerebral Cortex drug effects physiopathology MeSH
- Brain Waves drug effects MeSH
- Animals, Newborn MeSH
- Pilocarpine MeSH
- Piperidines pharmacology MeSH
- Rats, Wistar MeSH
- Receptors, N-Methyl-D-Aspartate antagonists & inhibitors MeSH
- Status Epilepticus chemically induced drug therapy physiopathology MeSH
- Age Factors MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
BACKGROUND: Ifenprodil as a specific antagonist of NMDA receptors containing a dominant NR2B subunit exhibits age-dependent anticonvulsant action. Possible changes of this action due to status epilepticus (SE) elicited at early stage of development were studied using cortical epileptic afterdischarges (ADs) as a model. METHODS: Lithium-pilocarpine SE was induced at postnatal day 12 and effects of ifenprodil were studied 3, 6, 9, and 13 days after SE in rat pups with implanted epidural electrodes. Controls (LiPAR) received saline instead of pilocarpine. ADs were elicited by low frequency stimulation of sensorimotor cortex. Intensity of stimulation current increased in 18 steps from 0.2 to 15 mA. Ifenprodil (20 mg/kg) was administered intraperitoneally (ip) after the stimulation with 3.5-mA current. Threshold for four different phenomena as well as duration of ADs were evaluated. RESULTS: The threshold for the transition into the limbic type of ADs was higher in 15-day-old SE rats than in LiPAR controls. Opposite difference was found in 18-day-old animals, older rats did not exhibit any difference. Isolated significant changes in total duration of ADs were found after high stimulation intensities. These changes appeared in 18-day-old rats where ADs were shorter in SE than in control LiPAR rats. CONCLUSIONS: Changes in ifenprodil action were found only in the first week after SE but not in the second week. Interpretation of the results is complicated by failure of significant differences between SE and LiPAR rats probably due to a high dose of paraldehyde.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033379
- 003
- CZ-PrNML
- 005
- 20181017160311.0
- 007
- ta
- 008
- 181008s2018 pl f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pharep.2017.08.012 $2 doi
- 035 __
- $a (PubMed)29355816
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a pl
- 100 1_
- $a Abbasova, Kenul $u Department of Developmental Epileptology, Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Faculty of Biology, Moscow State University, Moscow, Russia.
- 245 10
- $a Does status epilepticus modify the effect of ifenprodil on cortical epileptic afterdischarges in immature rats / $c K. Abbasova, H. Kubová, P. Mareš,
- 520 9_
- $a BACKGROUND: Ifenprodil as a specific antagonist of NMDA receptors containing a dominant NR2B subunit exhibits age-dependent anticonvulsant action. Possible changes of this action due to status epilepticus (SE) elicited at early stage of development were studied using cortical epileptic afterdischarges (ADs) as a model. METHODS: Lithium-pilocarpine SE was induced at postnatal day 12 and effects of ifenprodil were studied 3, 6, 9, and 13 days after SE in rat pups with implanted epidural electrodes. Controls (LiPAR) received saline instead of pilocarpine. ADs were elicited by low frequency stimulation of sensorimotor cortex. Intensity of stimulation current increased in 18 steps from 0.2 to 15 mA. Ifenprodil (20 mg/kg) was administered intraperitoneally (ip) after the stimulation with 3.5-mA current. Threshold for four different phenomena as well as duration of ADs were evaluated. RESULTS: The threshold for the transition into the limbic type of ADs was higher in 15-day-old SE rats than in LiPAR controls. Opposite difference was found in 18-day-old animals, older rats did not exhibit any difference. Isolated significant changes in total duration of ADs were found after high stimulation intensities. These changes appeared in 18-day-old rats where ADs were shorter in SE than in control LiPAR rats. CONCLUSIONS: Changes in ifenprodil action were found only in the first week after SE but not in the second week. Interpretation of the results is complicated by failure of significant differences between SE and LiPAR rats probably due to a high dose of paraldehyde.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a novorozená zvířata $7 D000831
- 650 _2
- $a antikonvulziva $x farmakologie $7 D000927
- 650 _2
- $a mozkové vlny $x účinky léků $7 D058256
- 650 _2
- $a mozková kůra $x účinky léků $x patofyziologie $7 D002540
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a elektrická stimulace $7 D004558
- 650 _2
- $a antagonisté excitačních aminokyselin $x farmakologie $7 D018691
- 650 _2
- $a chlorid lithný $7 D018021
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a pilokarpin $7 D010862
- 650 _2
- $a piperidiny $x farmakologie $7 D010880
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a receptory N-methyl-D-aspartátu $x antagonisté a inhibitory $7 D016194
- 650 _2
- $a status epilepticus $x chemicky indukované $x farmakoterapie $x patofyziologie $7 D013226
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kubová, Hana $u Department of Developmental Epileptology, Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Mareš, Pavel $u Department of Developmental Epileptology, Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Electronic address: maresp@biomed.cas.cz.
- 773 0_
- $w MED00165879 $t Pharmacological reports PR $x 1734-1140 $g Roč. 70, č. 1 (2018), s. 126-132
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29355816 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181017160810 $b ABA008
- 999 __
- $a ok $b bmc $g 1340895 $s 1030373
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 70 $c 1 $d 126-132 $e 20170826 $i 1734-1140 $m Pharmacol. Reports $n Pharmacol. Rep. $x MED00165879
- LZP __
- $a Pubmed-20181008